Batavia Bioservices changes name to Batavia Biosciences
Posted: 24 April 2015 | Victoria White (European Pharmaceutical Review)
Batavia Bioservices has changed its name to Batavia Biosciences as of 23 April 2015. The change will coincide with the launch of a new website and multimedia communication strategy.
Since its establishment in 2009, the company has experienced rapid growth and has established itself as a globally recognised and reliable partner for biotech companies, large pharmaceutical companies, government agencies, and academia.
Batavia Biosciences is recognised for the added value that the company brings to its partnerships, utilising in-depth knowledge of developing and manufacturing complex biopharmaceuticals, including recombinant proteins, antibodies, vaccines and vectors. The unique technologies the company possesses including STEP™ and SCOUT™ also facilitate accelerated product development at reduced cost and a significant increase in the success of an ultimate product launch.
New name, Batavia Biosciences, better reflects the Company’s scientific contribution to biotechnology projects
“Our new name, Batavia Biosciences, better reflects the added value and scientific support that our company brings to our partners as well as our R&D staff’s efforts in developing exciting novel technologies to accelerate biopharmaceutical product development”, commented Menzo Havenga, CEO.
“Our highly educated and experienced R&D staff is well recognised for their intellectual input in solving challenges early on in the process of developing novel or biosimilar biopharmaceuticals”, added Chris Yallop, COO.
Vincent Franssen, Commercial Director, Europe & Asia: “The name change is in keeping with a new and clear positioning of Batavia Biosciences’ scientific contribution to our customers biotechnology projects”.
A multimedia communication strategy will be rolled out over the coming months.
